Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00579228 · ClinicalTrials.gov registry record
Vascular Risk Progression in Normal and Diabetic Control Subjects.
A clinical trial, sponsored by University of Nebraska.
- Completed
- Registry status
- 90
- Enrollment target
NCT00579228: Completed study, sponsored by University of Nebraska.
NCT00579228 is a clinical trial that has completed, run by University of Nebraska. The registered enrollment target is 90 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00579228 has completed, sponsored by University of Nebraska.
- COMPLETED
- Registry status
- 90 participants
- Enrollment target
Study Summary
The purpose of this study is to look at the progression of cardiovascular disease (CVD) in normal control individuals and in patients with controlled diabetes.
Primary Outcome
To describe carotid intima media measurement change over 2 year period in normal individuals compared to individuals with well controlled diabetes
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2007-04-25 |
| Est. Completion | 2018-03-29 |
What the finished NCT00579228 record still lists
NCT00579228 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 90 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT00579228 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00579228 about?
NCT00579228 is a clinical study titled "Vascular Risk Progression in Normal and Diabetic Control Subjects.". The purpose of this study is to look at the progression of cardiovascular disease (CVD) in normal control individuals and in patients with controlled diabetes.
What is the current status of trial NCT00579228?
This trial is currently completed. The enrollment target is 90 participants. The study started on 2007-04-25. Estimated completion is 2018-03-29.
Who is sponsoring clinical trial NCT00579228?
This trial is sponsored by University of Nebraska, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI